DSIP: Side Effects & Safety

DSIP (Delta Sleep Inducing Peptide; pyr-Glu-Ala-Gly-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nine-amino-acid neuropeptide originally isolated from rabbit cerebral venous blood during sleep induction experiments in the 1970s.^[1] It is an endogenous compound in humans. Most of the published clinical literature on exogenous DSIP comes from the 1980s and early 1990s, primarily from European researchers, using older trial methodologies and small sample sizes.^[2]

DSIP is on the FDA's radar in 2026 under the name Emideltide — both the free base and acetate salt forms of Emideltide (DSIP) are scheduled for discussion at the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting (docket FDA-2025-N-6895) for potential inclusion on the 503A bulks list. If the committee recommends and FDA finalizes inclusion, DSIP could become legally compoundable by licensed US pharmacies with a valid prescription — moving it out of the current "research only" gray zone.

Effect	Frequency in published trials	Notes
Mild residual drowsiness (when dosed for sleep)	Common	Milder than benzodiazepines or Z-drugs
Vivid or unusual dreams	Common	Consistent with changes in sleep architecture; some users find this distressing
Mild headache	Uncommon	Usually transient, first few doses
Mild mood change (variable direction)	Uncommon	Both improvements and mild dysphoria reported
Injection-site reactions	Common at site	Standard subcutaneous
Dose-dependent hormone modulation	Documented in early studies	See endocrine section below
Tolerance with continuous daily dosing	Reported anecdotally	Cycling may preserve effect

No serious adverse events have been reported in the published literature at typical research doses (25–100 mcg SC). Sample sizes in the historical literature are small and modern Phase 3 safety standards have never been applied to DSIP.

One of the more interesting and less-discussed aspects of DSIP is its documented influence on multiple hormonal axes. Older studies report:

• Cortisol: reductions in plasma cortisol levels and dampening of stress-response cortisol surges in some studies.
• Growth hormone: modest stimulatory effect on GH secretion during sleep, possibly via hypothalamic mechanisms.
• Luteinizing hormone: some studies show LH modulation; clinical significance unclear.
• Somatostatin and prolactin: effects reported but inconsistent.

These hormonal interactions are usually modest at research doses and are not commonly reported as problematic by users. However, they do justify caution in patients with:

• Adrenal insufficiency (could compound cortisol-lowering effect).
• Existing growth hormone therapy.
• Pituitary disorders or known HPA dysfunction.

• Pregnancy and breastfeeding: no controlled data. Contraindicated.
• Adrenal insufficiency: theoretical concern given cortisol-lowering effects.
• Concurrent sleep medication use: theoretical additive sedation with benzodiazepines, Z-drugs, opioids, and alcohol — though DSIP itself is not strongly sedating.
• Active major depressive disorder, bipolar disorder, or severe insomnia: not a substitute for evidence-based first-line treatment.
• Severe hepatic or renal impairment: not studied.
• Known hypersensitivity to DSIP or formulation excipients.

Drug interactions

• Benzodiazepines, Z-drugs, opioids: theoretical additive sedation. DSIP itself does not strongly depress CNS but combinations are poor practice.
• Antihypertensives: minor BP-lowering effect documented in some early studies; monitor BP on initiation.
• Other peptides modulating GH or cortisol: theoretical additive endocrine effects.

• Residual morning drowsiness: reduce dose or shift timing earlier in the evening.
• Vivid or distressing dreams: reduce dose or discontinue if persistent.
• Mood worsening: discontinue and evaluate other causes.
• Persistent fatigue, low mood, or sluggishness during the day: consider HPA axis evaluation if symptoms persist after discontinuation.
• Allergic reaction: discontinue immediately and seek evaluation.

See the DSIP complete guide, dosage protocols, benefits and research, and the peptides for sleep overview. See also peptide legal status for context on the upcoming FDA Pharmacy Compounding Advisory Committee vote.